SCHEMBL17755053

SCHEMBL17755053

COc1ccccc1C(C)CC(=O)Nc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.55
▸ ALDH1A1 P00352 4/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ HPGD P15428 3/20 0.54
▸ HDAC3 O15379 1/20 0.53
▸ HDAC4 P56524 1/20 0.53
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC7 Q8WUI4 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ HDAC10 Q969S8 1/20 0.53
▸ HDAC11 Q96DB2 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ HDAC9 Q9UKV0 1/20 0.53
▸ HDAC5 Q9UQL6 1/20 0.53
▸ KMT2A Q03164 2/20 0.52
▸ TSHR P16473 1/20 0.51
▸ NPSR1 Q6W5P4 4/20 0.50
▸ HTT P42858 3/20 0.50
▸ MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1207026 0.81 POLB (0.57) LMNAALDH1A1L3MBTL1HPGDKMT2A
SCHEMBL30040417 0.81 POLB (0.57) LMNAALDH1A1L3MBTL1HPGDKMT2A
SCHEMBL17754986 0.80 HTT (0.51) LMNAALDH1A1L3MBTL1HPGDKMT2A
SCHEMBL17755051 0.79 KMT2A (0.57) LMNAALDH1A1HPGDKMT2AMEN1
SCHEMBL17755173 0.78 NOTUM (0.62) LMNAALDH1A1HDAC3HDAC4HDAC1
SCHEMBL5907668 0.77 HPGD (0.67) LMNAALDH1A1HPGDHDAC3HDAC4
SCHEMBL14826375 0.77 LMNA (0.73) LMNAALDH1A1L3MBTL1HPGDKMT2A
SCHEMBL17755257 0.76 POLB (0.51) LMNAL3MBTL1HPGDKMT2ANPSR1
SCHEMBL28652196 0.76 HPGD (0.61) LMNAALDH1A1HPGDHDAC3HDAC4
SCHEMBL27602952 0.76 L3MBTL1 (0.51) LMNAALDH1A1L3MBTL1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2021-02-11 — — US disclosed
US-10723708-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-07-28 — — US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 — — US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 — — US disclosed
WO-2016077240-A2 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC (US) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723708-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 LMNA 1477/4885ALDH1A1 3921/4885L3MBTL1 2803/4885
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 LMNA 1477/4885ALDH1A1 3921/4885L3MBTL1 2803/4885
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 LMNA 1477/4885ALDH1A1 3921/4885L3MBTL1 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback